Although small bowel polyps and tumors are rare, their incidence has increased significantly over the past 30 years. Small bowel malignancies can be classified depending upon their cellular origin into four principal histologic types: adenocarcinomas, lymphomas, neuroendocrine tumors or carcinoids and lymphomas, which also include gastrointestinal stromal tumors. The relative ‘rarity' of these tumors has led to stagnation in the development of effective curative or adjuvant therapies. Thus, the prognosis of most of these tumors is still dismal. Nevertheless, hope is now on the horizon as new methods such as capsule endoscopy and balloon-assisted enteroscopy have contributed to a rise in the diagnosis of these lesions and a diagnosis at earlier stages. Using balloon-assisted enteroscopy methods it is possible to resect most small bowel polyps such as adenomas and hamartomas. Improved imaging methods have led to a better understanding of these pathologies and hopefully will bring new hopes in therapy. In addition, multi-center studies are being performed to determine the best therapeutic options for small bowel tumors. Key Message New imaging techniques such as capsule endoscopy and balloon-assisted endoscopy have facilitated the early diagnosis of small bowel malignancies, leading to a better understanding of the biology of these tumors and to improved clinical outcomes for the patient. Practical Implications Although relatively rare, the incidence of tumors and polyps in the small intestine has increased over the past 20 years. The use of endoscopic or radiologic techniques is crucial for the detection and resection of polyps. It is highly recommended to perform a submucosal injection of epinephrine-saline solution prior to endoscopic resection. Due to their non-specific symptoms, neuroendocrine tumors are often diagnosed in advanced stages; surgical excision of the primary tumor is key to a better prognosis. The main therapies for neuroendocrine tumors are surgery, chemoembolization, chemotherapy and the use of somatostatin analogues. Small bowel adenocarcinomas are extremely rare but can be highly fatal. Surgical resection is still the core treatment, though fluoropyrimidine and oxaliplatin-based chemotherapy have shown beneficial effects for the treatment of metastatic disease. Amongst the gastrointestinal stromal tumors, 30% are located in the small intestine. The management of gastrointestinal stromal tumors requires a combination of surgery, pathology techniques and pharmacological interventions, including the use of tyrosine kinase inhibitors.

Keywords:
Gastrointestinal stromal tumor, Neuroendocrine tumor, Peutz-Jeghers syndrome, Small bowel adenocarcinoma, Small bowel polyps
1.
Zureikat AH, Heller MT, Zeh HJ III: Cancer of the small intestine; in DeVita VT Jr, Lawrence TS, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, ed 9. Philadelphia, Lippincott Williams & Wilkins, 2011, pp 1048-1059.
2.
Aparicio T, Zaanan A, Svrcek M, Laurent-Puig P, Carrere N, Manfredi S, Locher C, Afchain P: Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis DOI: 10.1016/j.dld.2013.04.013.
3.
Haselkorn T, Whittemore AS, Lilienfeld DE: Incidence of small bowel cancer in the United States and worldwide: geographic, temporal, and racial differences. Cancer Causes Control 2005;16:781-787.
4.
Severson RK, Schenk M, Gurney JG, Weiss LK, Demers RY: Increasing incidence of adenocarcinomas and carcinoid tumors of the small intestine in adults. Cancer Epidemiol Biomarkers Prev 1996;5:81-84.
5.
Fry LC, Bellutti M, Neumann H, Malfertheiner P, Mönkemüller K: Incidence of bleeding lesions within reach of conventional upper and lower endoscopes in patients undergoing double-balloon enteroscopy for obscure gastrointestinal bleeding. Aliment Pharmacol Ther 2009;29:342-349.
6.
van Tuyl SA, van Noorden JT, Timmer R, Stolk MF, Kuipers EJ, Taal BG: Detection of small-bowel neuroendocrine tumors by video capsule endoscopy. Gastrointest Endosc 2006;64:66-72.
7.
Achour J, Serraj I, Amrani L, Amrani N: Small bowel tumors: what is the contribution of video capsule endoscopy? Clin Res Hepatol Gastroenterol 2012;36:222-226.
8.
Almeida N, Figueiredo P, Lopes S, Gouveia H, Leitão MC: Double-balloon enteroscopy and small bowel tumors: a South-European single-center experience. Dig Dis Sci 2009;54:1520-1524.
9.
Zouhairi ME, Venner A, Charabaty A, Pishvaian MJ: Small bowel adenocarcinoma. Curr Treat Options Oncol 2008;9:388-399.
10.
Piscaglia AC, Campanale M, Gasbarrini G: Small bowel nonendocrine neoplasms: current concepts and novel perspectives. Eur Rev Med Pharmacol Sci 2010;14:320-326.
11.
Fry LC, Neumann H, Kuester D, Kuhn R, Bellutti M, Malfertheiner P, Mönkemüller K: Small bowel polyps and tumours: endoscopic detection and treatment by double-balloon enteroscopy. Aliment Pharmacol Ther 2009;29:135-142.
12.
Mönkemüller K, Fry LC, Neumann H: Endoscopic management of premalignant, early and advanced malignancies of the small bowel; in Deutsch JC, Banks MR (eds): Gastrointestinal Endoscopy in the Cancer Patient. Oxford, Wiley-Blackwell, 2013, pp 114-120.
13.
Saurin JC, Gutknecht C, Napoleon B, Chavaillon A, Ecochard R, Scoazec JY, Ponchon T, Chayvialle JA: Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol 2004;22:493-498.
14.
Mönkemüller K, Fry LC, Ebert M, Bellutti M, Venerito M, Knippig C, Rickes S, Muschke P, Röcken C, Malfertheiner P: Feasibility of double-balloon enteroscopy-assisted chromoendoscopy of the small bowel in patients with familial adenomatous polyposis. Endoscopy 2007;39:52-57.
15.
Bellutti M, Fry LC, Schmitt J, Seemann M, Klose S, Malfertheiner P, Mönkemüller K: Detection of neuroendocrine tumors of the small bowel by double balloon enteroscopy. Dig Dis Sci 2009;54:1050-1058.
16.
Demirkan BH, Eriksson B: Systemic treatment of neuroendocrine tumors with hepatic metastases. Turk J Gastroenterol 2012;23:427-437.
17.
Trikudanathan G, Dasanu CA: Evolving pharmacotherapeutic strategies for small bowel adenocarcinoma. Expert Opin Pharmacother 2010;11:1695-1704.
18.
Gore RM, Mehta UK, Berlin JW, Rao V, Newmark GM: Diagnosis and staging of small bowel tumours. Cancer Imaging 2006;6:209-212.
19.
Jovanovic I, Fry LC, Mönkemüller K: Small-bowel adenocarcinoma. Clin Gastroenterol Hepatol 2011;9:A28.
20.
Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA: Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 2008;113:2038-2045.
21.
Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA: Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol 2010;49:474-479.
22.
Jovanovic I, Krivokapic Z, Menkovic N, Krstic M, Mönkemüler K: Ineffectiveness of capsule endoscopy and total double-balloon enteroscopy to elicit the cause of obscure overt gastrointestinal bleeding: think GIST! Endoscopy 2011;43(suppl 2 UCTN):E91-E92.
23.
Joensuu H, Hohenberger P, Corless CL: Gastrointestinal stromal tumour. Lancet DOI: 10.1016/S0140-6736(13)60106-3.
24.
Pisters PW, Patel SR: Gastrointestinal stromal tumors: current management. J Surg Oncol 2010;102:530-538.
25.
Mullady DK, Tan BR: A multidisciplinary approach to the diagnosis and treatment of gastrointestinal stromal tumor. J Clin Gastroenterol 2013;47:578-585.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.